ERBB2 and breast cancer: In an investigation undertaken by Meiyanto et al.[55], doxorubicin-resistant breast cancer cell lines MCF-7/Dox cells with over-expression of HER2 were tested against doxorubicin (IC50 = 7) and curcumin (IC50 = 80 ± 2.39) separately and in combination.